Tucson Media Briefing on Trial Results From Therapeutic HIV Vaccine
WHO: Dr. Eduardo Fernandez-Cruz, Professor and Head of the Division
of Immunology at University General Hospital Gregorio Maranon,
Madrid, Spain and principle investigator of a Phase II clinical
trial of REMUNE(R), a therapeutic vaccine for HIV
Dr. Ronald B. Moss, vice president of medical and scientific
affairs, The Immune Response Corporation and one of the
co-chairs for the 2002 FASEB Summer Research Conference on
Therapeutic and Preventive AIDS vaccines
WHAT: Media briefing on results of recent Phase II clinical trial in
Spain on REMUNE(R), a potentially beneficial therapeutic vaccine
for HIV
Estimates at the recent International AIDS Conference in
Barcelona indicate that over 40 million people worldwide are
infected with HIV with almost one million of them in the U.S.
alone
Dr. Fernandez-Cruz and Dr. Moss are presenting data at the 2002
Federation of American Societies for Experimental Biology's
(FASEB) Summer Research Conference on Therapeutic and Preventive
HIV Vaccines, co-sponsored by the National Institutes for
Health's Office of AIDS Research
WHEN: Tuesday, July 30, 2002
11:00 a.m.
WHERE: Papago Ballroom
Omni Tucson National Golf Resort & Spa
2727 W. Club Drive
Tucson, AZ
Media: James Lee
The Lee Strategy Group
Ph (310) 229-5771
Fax (310) 229-5772
Email: jlee@leestrategy.com
Investors: Kathy Lane
The Immune Response Corporation
Ph (760) 771-2236
Fax (760) 771-2140
Email: info@imnr.com
SOURCE The Immune Response Corporation
back to top
